site sponsored by
Drug companies don’t have the luxury of waiting for the FDA to issue guidelines on marketing
Posted on 07 December 2009
Source: World of DTC Marketing
Categories: DTC
Leave a Reply
Ask Our Experts
Heather R. Powell
Regulatory
Dawn Obermoeller
Social Media
Jonathan Richman
Non-Personal Promotion
Optimize RX
Internet Marketing & Analytics
Share Your Knowledge
We are always seeking seasoned pharmaceutical marketing professonals as contributors. If you have a strong background in pharmacetical marketing, and are interested in sharing your skills and knowledge with our community, or syndicating your existing blog posts, please click here.
- Popular
- Latest
- Comments
- Tags
- Subscribe
- Let’s Just Spread This Deal Out All Over the Paper, Why Don’t We?
- Design: Flash-banner-eyebrow nightmare
- Even After Patent Cliff, Pfizer Is Undervalued
- Sanofi Board Said to Support Genzyme Bid of Up to $18.7 Billion
- FTC: âTide May Be Turningâ On Pay-To-Delay Deals
- Celgene Beats and Raises Guidance
- Who is Killing the Pharmaceutical Sales Position?
- Snafi – HCP print ad in the UAE
- Hospira plans big study for new Epogen biosimilar
- New from OSI / Astellas
- Optimize RX: yep - recvd - thanks - how much daily u.v.'s r u g...
- JMB: This is another bashing article from an author who...
- Martin: It's just silly of you to obsess over the possibil...
- Gregg Feris: Jon, Thanks for the in depth reply. I like the ...
- Doc: Why should Exxon have to pay this fine for somethi...
2009
adpharm
adpharm gallery
advertising
alpha
biotech
bnet
branded
business
development
drug
DTC
english
europe
fda
fierce-biotech
fierce pharma
gallery
hcp
health
industry
internet
largest
marketing
motley-fool
News
north
north america
north_america
online
online-pharmaceutical
pharma
Print
print_ad
Regulatory
sales
seeking-alpha
single-page
Social Media
technology
the-gallery
the-largest
time
usa
wsj
Stay up to date
- Subscribe to the RSS Feed
